Search PubMed⌕ Search

Biomedical subjects

B Mann

Publications and source records attributed to B Mann.

75 records · Page 5Linked to original sources
PubMedDate not supplied

Pilar tumour: a distinctive type of trichilemmoma.

A series of pilar tumours is presented. Although they are predominantly tumours of the elderly female, they occur also in men and in middle age. Some 90 per cent occur on the scalp or nape of neck; about 10 per cent affect other areas. Most tumours outside the scalp involve the trunk; they are rare on the extremities. Evidence is presented that most arise from pre-existing pilar cysts. Two tumours recurred, but were cured by re-excision. Four tumours exhibited histological and/or cytological criteria of malignancy. Two of these were interpreted as in situ carcinomas, and two as combined invasive and in situ carcinomas. None is known to have metastasized or to have behaved aggressively. The prognosis of pilar tumours in excellent whatever the histological appearance. The nature of the lesion and the problems of nomenclature associated with it are discussed.

Adult↗
PubMedDate not supplied

Urodilatin, a new therapy to prevent kidney failure after heart transplantation.

Kidney failure after heart transplantation still remains a crucial problem, especially when cyclosporine is used for early postoperative immunosuppressive therapy. To preserve good renal function during immunosuppression with cyclosporine, urodilatin (CDD/ANP-95-126), the kidney-born analogue to the circulating cardiac peptide hANP (CDD/ANP-99-126), was given for the first time as a long-term, low-dose infusion in addition to the usual drug therapy immediately after heart transplantation. From November 1990 to January 1992, 47 patients (44 men and three women; mean age, 51 years) were treated by a 20 ng/kg body weight/min infusion for 96 hours after heart transplantation. Renal function and hemodynamic parameters of these patients were compared with a group of 40 patients (34 male and six female; mean age, 50 years) as controls, who underwent heart transplantation from May 1990 to November 1991. Both groups did not differ significantly with respect to age, sex, indication for heart transplantation, and preoperative renal function. With urodilatin treatment, renal function was significantly improved with lower peak plasma creatinine (1.83 +/- 0.1 versus 2.47 +/- 0.19 mg/dl; p = 0.003), lower peak serum urea (118 +/- 7 versus 178.3 +/- 10.3 mg/dl; p = 0.0036) and absence of hemodialysis (0% versus 10%; p = 0.026). Additionally, adequate diuresis was maintained although furosemide was reduced by more than 50% (p = 0.005) on each day of urodilatin treatment. Mean central venous pressure was significantly lower (-2 mm Hg; p = 0.02) during application of urodilatin, despite reduction of vasodilator therapy with nitroglycerin by about 50% (p = 0.02). Because of the significantly improved renal function and beneficial hemodynamic effects, the recommendation is therefore to introduce urodilatin in the postoperative treatment protocol after heart transplantation.

Adult↗